RenovoRx, Inc. (RNXT) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. RenovoRx, Inc. is a life sciences company developing targeted oncology therapies and commercializing RenovoCath, an FDA-cleared local drug-delivery device. The company is also advancing its lead drug-device combination candidate, intra-arterial gemcitabine (IAG), in the Phase III TIGeR-PaC clinical trial for locally advanced pancreatic cancer. As of June 30, 2026, the company had 21 active commercial cancer centers utilizing RenovoCath.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|
| Revenue | $0.909 million | $1.472 million | $0.619 million |
| Gross Profit | $0.766 million | $1.245 million | $0.373 million |
| Gross Margin | 84.3% | 84.6% | 60.3% |
| Net Loss | $(2.911) million | $(6.432) million | $(5.315) million |
| Cash and Equivalents | $9.479 million (as of June 30, 2026) | ||
| Accumulated Deficit | $(67.819) million (as of June 30, 2026) | ||
| Operating Cash Flow | $(6.576) million used (YTD 2026) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 115% year-over-year for Q2 2026 and 138% for the six-month period, driven by the expansion of active commercial cancer centers (from 16 to 21 in Q2) and repeat ordering.
- Operating Expenses: Selling, General, and Administrative (SG&A) expenses rose significantly, increasing 92% in Q2 and 82% YTD compared to 2025, due to headcount expansion to support commercialization. Research and Development (R&D) expenses decreased 16% in Q2 and 21% YTD, primarily due to reduced regulatory and clinical development costs for the TIGeR-PaC trial.
- Financing Activity: In March 2026, the company completed a private placement raising approximately $10.0 million in gross proceeds, issuing common stock, pre-funded warrants, and revenue milestone warrants.
- Warrant Liability: The company recognized a non-cash gain of $0.350 million in Q2 2026 due to a decrease in the fair value of common stock warrant liabilities.
Outlook, Risks, and Management Commentary
- Commercial Outlook: Management expects revenue to grow sequentially for the remainder of 2026. The company aims to reach 36 active commercial cancer centers by year-end 2026. The total addressable market for RenovoCath as a standalone device is estimated at approximately $400 million in peak annual U.S. sales.
- Clinical Progress: Patient enrollment for the Phase III TIGeR-PaC trial is closing. The trial is expected to complete in the first half of 2027, with top-line data anticipated in the second half of 2027. The company recently began a new investigator-initiated trial for cholangiocarcinoma (bile duct cancer).
- Liquidity: With $9.5 million in cash as of June 30, 2026, management believes current resources are sufficient to fund operations for at least the next 12 months (into the second half of 2027). However, the company expects to continue incurring losses and may require additional capital in the future.
- Nasdaq Compliance Risk: The company is currently not in compliance with the Nasdaq minimum bid price requirement ($1.00 per share). It has been granted a second compliance period until December 28, 2026. Failure to regain compliance could result in delisting. The company may consider a reverse stock split to regain compliance.
Key Facts for Investor Verification
- Revenue Sustainability: Verify the durability of the 115% revenue growth and the rate of new active cancer center acquisitions to ensure the path to profitability is viable.
- Nasdaq Listing Status: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement by December 28, 2026, to avoid delisting risks.
- Cash Burn Rate: Assess the net cash burn from operations ($6.6M YTD) against the $9.5M cash balance to confirm the 12-month runway estimate.
- Clinical Trial Milestones: Track the completion of the TIGeR-PaC trial enrollment and the timeline for top-line data release in late 2027.
- Customer Concentration: Note that four customers accounted for over 50% of revenue in the first half of 2026, indicating high concentration risk.